RNAi specialist Arrowhead reports loss of $58.7M in FY 2014

Arrowhead Research ($ARWR) reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013. R&D expenses nearly tripled in FY 2014 to $23.1 million, as the company races to develop a commercial therapy before investors lose patience. Its stock fell about 50 cents on the Nov. 25 news and now stands at a little under $6. Release

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.